Shanghai Henlius Biotech (HKSE:02696) Additional Paid-In Capital : HK$6,480 Mil(As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Additional Paid-In Capital?

Shanghai Henlius Biotech's quarterly additional paid-in capital declined from Dec. 2023 (HK$6,639 Mil) to Jun. 2024 (HK$6,534 Mil) but then stayed the same from Jun. 2024 (HK$6,534 Mil) to Dec. 2024 (HK$6,480 Mil).

Shanghai Henlius Biotech's annual additional paid-in capital declined from Dec. 2022 (HK$6,758 Mil) to Dec. 2023 (HK$6,639 Mil) and declined from Dec. 2023 (HK$6,639 Mil) to Dec. 2024 (HK$6,480 Mil).

Shanghai Henlius Biotech Additional Paid-In Capital Historical Data

The historical data trend for Shanghai Henlius Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Additional Paid-In Capital Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

6,758.09

6,638.56

6,480.11

Shanghai Henlius Biotech Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial										6,758.09	6,638.57	6,638.56	6,533.96	6,480.11

Shanghai Henlius Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Shanghai Henlius Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Ubs Group Ag
Golden Valley Value Select Master Fund	2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited	2301 Trustee
Lvc Sg Management Pte. Ltd.	2201 Interest of corporation controlled by you
Lvc Management Holdings Limited	2201 Interest of corporation controlled by you
Lin Lijun	2201 Interest of corporation controlled by you
Qatar Investment Authority	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines